Advertising
Showing 1 to 15 of 174 entries
PAST TOP PICK
(A Top Pick Oct 20/20, Up 30%) Quality company. Concerns have abated. Catalyst coming up with cardio drug in the second half of the year. Not very expensive.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Mar 17/22, Up 8%) In the US there's a violent rotation into the drug space that will continue. He models $116, so huge upside.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Dec 23/21, Up 16.2%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with BMY has achieved its $72.50 objective. To remain disciplined, we recommend covering half the position at this time and trailing up the stop (from $58) to $68.
biotechnology / pharmaceutical
TOP PICK
Likes the drug space in general. Model price of $112, up from today's price of around $70, a 61% upside. Buys back a lot of stock. Huge value. No pullback despite market volatility in last 3 months. You get paid to wait, and in USD. Yield is 3.07%. (Analysts’ price target is $73.42)
biotechnology / pharmaceutical
COMMENT
They have done well recently but he is looking for companies with longer term potential and expiry dates for drug patents. Should have good pipelines. Prefers diabetic care companies since this disease is on the rise. eg. Eli Lilly or Novo Nordisk. Astra Zeneca has a good pipeline in oncology drugs.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Dec 23/21, Up 10.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with BMY is progressing well. We now recommend trailing up the stop (from $54) to $58.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly We reiterate BMY, a $139 billion marketcap pharma player, as a TOP PICK. The recent $13 billion acquisition of a company that focuses on blood cancer treatment has gone well, but analysts have held the stock value back as the drug will lose patent protection in 2023. If you believe in the strength of management this will not be a game changer. Recent reported earnings beat market expectations by 4% and its ROE is over 40%. It pays a good dividend that has grown over 40% over the past three years. We would continue to use $54 as a stop-loss, looking to achieve $72.50 -- over 16% upside. Yield 3.19% (Analysts’ price target is $72.50)
biotechnology / pharmaceutical
BUY
Likes this pharma. It offers decent dividend growth and the dividend is safe. He holds pharma long term and didn't sell during Covid. Post-Covid, focus will return to non-Covid drugs, like BMY's cancer treatment.
biotechnology / pharmaceutical
BUY
Up 9.5% for the year, and is benefiting from the expected decree from Washington for Covid booster shots to fight Covid. So, BMY is rising because the entire drug space is rising. They also have a consistent track record, consistent dividend and anti-cancer drug.
biotechnology / pharmaceutical
COMMENT
They report Friday. He likes the CEO, but isn't sure if this stock can break from the pack.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Jan 22/20, Down 8%) Sexier areas of the market pulled money away from the boring companies. Over the next decade, sees a fantastic R&D pipeline of cancer drugs. Tremendous cashflow will be deployed in R&D and acquisitions to augment their growth profile. Stick with it to collect the dividend with some slow growth.
biotechnology / pharmaceutical
HOLD

Diversified large cap. A lot of businesses working really well. Celgene acquisition diversified their oncology. Main drug is performing well. Trading at 8.5x forward earnings, with low double digit EPS growth. One of his core holdings.

biotechnology / pharmaceutical
BUY

It was up nearly 4% today during JPMorgan's healthcare conference. BMY delivered good news. Management announced strong early revenue goals for new products, including three new drugs that could hit $4 billion in sales this decade. Their strong pipeline of drugs was bulked by buying Celgene and MyoKardia. They also announced a bullish free cash-flow forecasts for coming years which will buyback shares and pay down debt. For years, this has failed to break out from mid-$60s, but that could change.

biotechnology / pharmaceutical
TOP PICK

He liked their Celgene acquisition last year (though the market didn't), because it diversified their exposure to other drugs which have exectued well. Their R&D and core business are doing well. The stock trades at only 8x earnings. There is a disconnect between company performance and the market. It's very cheap and they execute well. (Analysts’ price target is $72.93)

biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly This household pharma player has just made a $13 billion acquisition of a company that focuses on the treatment of irregular heart rhythms -- something that doesn't have another treatment option yet. This will go to diversify the company's success in the cancer treatment field. With an outlook to earnings growth of over 17% next year the Price to Earnings Growth Ratio is just 1.1 -- suggesting good value at these levels. We would trade this with a $54 stop-loss. Yield 3.04% (Analysts’ price target is $73.62)
biotechnology / pharmaceutical
Showing 1 to 15 of 174 entries

Bristol Myers Squibb(BMY-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 6

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 6

Stockchase rating for Bristol Myers Squibb is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Bristol Myers Squibb(BMY-N) Frequently Asked Questions

What is Bristol Myers Squibb stock symbol?

Bristol Myers Squibb is a American stock, trading under the symbol BMY-N on the New York Stock Exchange (BMY). It is usually referred to as NYSE:BMY or BMY-N

Is Bristol Myers Squibb a buy or a sell?

In the last year, 6 stock analysts published opinions about BMY-N. 6 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Bristol Myers Squibb.

Is Bristol Myers Squibb a good investment or a top pick?

Bristol Myers Squibb was recommended as a Top Pick by on . Read the latest stock experts ratings for Bristol Myers Squibb.

Why is Bristol Myers Squibb stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Bristol Myers Squibb worth watching?

6 stock analysts on Stockchase covered Bristol Myers Squibb In the last year. It is a trending stock that is worth watching.

What is Bristol Myers Squibb stock price?

On 2022-05-23, Bristol Myers Squibb (BMY-N) stock closed at a price of $76.7.